C-path global impact conference
Ended Project Grant Awarded Last action
- Award ID
- R13FD008427
- Recipient
-
The Critical Path Institute UEI KAEPADMRKHD3
- Awarding agency
-
FDA Office of Acquisition and Grant Services
Food and Drug Administration, Department of Health and Human Services
- Obligated
- $150,000
Award facts
- Assistance listing
- 93.103 Food and Drug Administration Research
- Completion date
- Funding agency
- Center for Biologics Evaluation and Research Food and Drug Administration, Department of Health and Human Services
- Place of performance
- Arizona, USA
Award details come from USAspending.gov.
Description
- Abstract
- Critical path institute (c-path) is an independent, nonprofit public-private partnership (PPP) with the U.S. Food and drug administration (FDA), with a mission to improve the efficiency and safety of medical product development. The purpose of the 4-day interdisciplinary conference, titled "c-path global impact conference" is to showcase the work done by several c-path public private partnerships (ppps) in generating actionable solutions to accelerate drug development. Additionally, this conference will feature c-path consortia current contributions towards the development of novel therapeutics for challenging conditions in neurology, rare and orphan conditions, and pediatric populations. This conference will be the largest and broadest reaching conference organized by c-path during the organization's nearly 20-year history. The c-path global impact conference will bring together and capitalize on the strong existing pre-competitive relationships between c- path and diverse stakeholders - including regulatory agencies (U.S. Food and drug administration [FDA], european medicines agency [EMA], japanese pharmaceuticals and medical devices agency [pdma]), pharmaceutical industries, academic researchers, non-profit organizations, and patient groups - to hold productive dialogue among the conference attendees and advance efforts to produce publicly available drug development tools to optimize the evaluation of the efficiency and safety of novel therapeutics. This conference will advance science and clinical practice through the interactive discussions between stakeholders, such as industry, academia, regulatory agencies, and patient groups. By spurring further productive dialogue regarding data sharing, standardizing methodologies, and the generation of actionable solutions for drug development across challenging therapeutic areas, this conference will position c-path's ppps to further accelerate the development and approval of new therapies, improve clinical trial efficiency, and enhance patient outcomes.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $150,000 |
Quick answers
Who received award R13FD008427?
R13FD008427 was awarded to The Critical Path Institute by FDA Office of Acquisition and Grant Services (Food and Drug Administration) on September 1, 2024.
How much is award R13FD008427 worth?
$150,000 has been obligated on R13FD008427.
Which agency awarded R13FD008427?
FDA Office of Acquisition and Grant Services (Food and Drug Administration) awarded R13FD008427, with funding from Center for Biologics Evaluation and Research (Food and Drug Administration).
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award